NOVEL FUSION GENES AS FACTORS RESPONSIBLE FOR GASTRIC CANCER

摘要

To identify mutations that can serve as indicators for predicting the effectiveness of drug treatments in cancers such as gastric cancer; to provide a means for detecting said mutations; and to provide a means for identifying, based on said mutations, patients with cancer or subjects with a risk of cancer, in whom drugs targeting genes having said mutations or proteins encoded by said genes show a therapeutic effect.;A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an ATG3-EPHB1 fusion polynucleotide, a TNIK-RNF123 fusion polynucleotide, or an SLC12A2-NRG2 fusion polynucleotide, or a polypeptide encoded thereby, in an isolated sample from a subject.

主权项

1. A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting a fusion polynucleotide of any one of (a) to (c) below, or a polypeptide encoded thereby, in an isolated sample from a subject:
(a) an ATG3-EPHB1 fusion polynucleotide which encodes a polypeptide comprising the kinase domain of EPHB1 and having kinase activity; (b) a TNIK-RNF123 fusion polynucleotide which encodes a polypeptide comprising the kinase domain of TNIK and the SPRY domain and RING finger domain of RNF123, and having kinase activity; and (c) an SLC12A2-NRG2 fusion polynucleotide which encodes a polypeptide comprising the AA_permease_N super family domain of SLC12A2 and the neuregulin family conserved region of NRG2, and having intracellular signaling-enhancing activity.